Avalo Therapeutics, Inc. Stock

Equities

AVTX

US05338F3064

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-21 EDT 5-day change 1st Jan Change
13.04 USD -1.66% Intraday chart for Avalo Therapeutics, Inc. +19.30% +43.30%
Sales 2024 * - Sales 2025 * - Capitalization 13.49M 18.47M
Net income 2024 * -33M -45.19M Net income 2025 * -36M -49.3M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-14.3 x
P/E ratio 2025 *
-13.4 x
Employees 19
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.66%
1 week+19.30%
Current month+11.60%
1 month+19.41%
3 months+183.48%
6 months+8.67%
Current year+43.30%
More quotes
1 week
10.30
Extreme 10.3
14.00
1 month
9.98
Extreme 9.98
14.00
Current year
3.95
Extreme 3.9501
34.46
1 year
3.95
Extreme 3.9501
1 130.39
3 years
3.95
Extreme 3.9501
10 540.72
5 years
3.95
Extreme 3.9501
17 827.06
10 years
3.95
Extreme 3.9501
22 031.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 20-01-31
Director of Finance/CFO 40 17-12-31
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 67 21-11-09
Director/Board Member 76 20-10-11
Chief Executive Officer 70 20-01-31
More insiders
Date Price Change Volume
24-06-21 13.04 -1.66% 34,856
24-06-20 13.26 +12.37% 40,231
24-06-18 11.8 +2.88% 22,600
24-06-17 11.47 +4.94% 28,142
24-06-14 10.93 -6.02% 17,497

Delayed Quote Nasdaq, June 21, 2024 at 04:00 pm

More quotes
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (AVTX-002) (anti-LIGHT monoclonal antibody (mAb)) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Quisovalimab shows reduction of Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT) levels, as well as a favorable safety and tolerability profile, in all indications studied including COVID-19 acute respiratory distress syndrome (ARDS), Crohn's Disease, and non-eosinophilic asthma (NEA).
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
13.04 USD
Average target price
35 USD
Spread / Average Target
+168.40%
Consensus